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Abstract
Background: Mutations in the gene encoding the nuclear membrane protein lamin A/C have been
associated with at least 7 distinct diseases including autosomal dominant dilated cardiomyopathy
with conduction system disease, autosomal dominant and recessive Emery Dreifuss Muscular
Dystrophy, limb girdle muscular dystrophy type 1B, autosomal recessive type 2 Charcot Marie
Tooth, mandibuloacral dysplasia, familial partial lipodystrophy and Hutchinson-Gilford progeria.
Methods: We used mutation detection to evaluate the lamin A/C gene in a 45 year-old woman
with familial dilated cardiomyopathy and conduction system disease whose family has been well
characterized for this phenotype [1].
Results: DNA from the proband was analyzed, and a novel 2 base-pair deletion c.908_909delCT
in LMNA was identified.
Conclusions: Mutations in the gene encoding lamin A/C can lead to significant cardiac conduction
system disease that can be successfully treated with pacemakers and/or defibrillators. Genetic
screening can help assess risk for arrhythmia and need for device implantation.
Background
Dilated cardiomyopathy (DCM) is a disorder character-
ized by four-chamber dilation of the heart. DCM is often
progressive and results in reduced heart function and con-
gestive heart failure. Although etiologically diverse, inher-
itance is a significant contributor to the development of
DCM. Supporting this, mutations in a number of different
genes have recently been associated with familial forms of
DCM [2], and mutations in the gene encoding lamin A/C
appear to be a significant component. Lamins A and C are
two different proteins produced by alternative splicing
from the same gene. They are identical along their first
566 amino acids and differ only in their carboxyl termi-
nus. As specialized proteins of the intermediate filament
protein family, lamin A/C is found at the inner nuclear
membrane where it forms a scaffold that interacts with a
network of membrane bound and nucleoplasmic proteins
in addition to chromatin [3–5]. Mutations in the gene
encoding the nuclear membrane protein emerin produce
autosomal recessive Emery Dreifuss Muscular Dystrophy,
a disorder that phenotypically overlaps the neuromuscu-
lar and cardiovascular features seen with lamin A/C muta-
tions [6]. Consistent with this, lamin A/C directly binds
emerin [7,8]. Lamins A and C are broadly expressed in
many different cell types and are primarily expressed in
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terminally differentiated cells. It is not known how muta-
tions in LMNA lead to tissue-specific phenotypes.
The first autosomal dominant form of cardiomyopathy
was mapped in 1994 to the centromeric region of chro-
mosome 1 [9]. Linkage was achieved using genetic and
clinical material from a large, well-characterized kindred
[1]. One of the striking characteristics from this family was
the degree of cardiac conduction system disease that pri-
marily targeted the atrioventricular node [1,10]. Many
members of the kindred exhibited sick sinus syndrome,
atrial fibrillation and sudden death.
In addition to DCM with conduction system disease and
variable skeletal muscle involvement, mutations in the
Lamin A/C gene [OMIM 150330] have been shown to
cause autosomal dominant [11] and autosomal recessive
[12] Emery-Dreifuss Muscular Dystrophy (EDMD), auto-
somal dominant limb-girdle muscular dystrophy type 1B
(LGMD) [13], autosomal recessive type 2 Charcot-Marie
Tooth type 2 [14], familial partial lipodystrophy [15,16],
Mandibuloacral dysplasia [17] and Hutchinson-Gilford
progeria [18]. The phenotypic spectrum from DCM to
EDMD and limb girdle muscular dystrophy appears con-
tinuous. However, the mechanism by which LMNA muta-
tions lead to cardiac versus skeletal muscle disease is
unknown.
We now evaluated a woman with DCM and sinus brady-
cardia. Her immediate family history was significant for
symptomatic bradycardia requiring pacemaker implanta-
tion. She is a member of the kindred initially described by
Graber et al [1]. We screened this individual for mutations
and found a novel mutation in exon 5 of LMNA. This two
bp deletion is predicted to disrupt the reading frame and
produce a truncated lamin A and C.
Methods
Patient recruitment
Written and informed consent was obtained in accord-
ance with the University of Chicago's Institutional Review
Board. Clinical data were obtained through evaluations
performed at the University of Chicago.
Genetic Analysis
DNA extraction from blood was performed using Pure-
Gene according to the manufacturer's recommendations.
PCR primers were designed to amplify all twelve protein
coding exons of LMNA (Table 1). DHPLC analysis of each
exon was carried out on a WAVE™ (Transgenomic); exon
5 was analyzed at 65.2°C with 51%-56%-65% ace-
tonitrile. SSCP was performed using MDE™ (FMC) as
described [19]. Direct sequencing of PCR products was
completed using cycle sequencing. To confirm the pres-
ence of the mutation, PCR products were purified and
digested with AlwN I.
Table 1: Primers for amplifying LMNA for DHPLC and SSCP analysis. All sequences are listed 5' to 3'.
Exon Primers
1A F:CCCAGATCCCGAGGTCCGAC
R:AGCCCTGCGTTCTCCGTTTCC
B F:ACCCGCATCACCCGGCTG
R:CCTCTCCACTCCCCGCCA
2 F:GCGGCCCGCCGCCCCCGCCGCTCCTTCTCTTAAATCTACTCTCC
R:GCGGCCCGCCGCCCCCGCCGGCTCTGAAATCAGGTGACAG
3 F:TGTTCTGTGACCCCTTTTCC
R:CCAGCCCAAGTCTGTCATC
4 F:AGCACTCAGCTCCCAGGTTA
R:CCGCCGCCCCCGCCCGGTAAGGGTAGGGCTGCCAAG
5 F:GCGGCCCGCCGCCCCCGCCGTAGCAGTGATGCCCAA
R:GCCCGCCGCCCCCGCCCGCATCCGGCCCAGACTCTA
6 F:GTCCCTCCTTCCCCATACTT
R:CCAAGTGGGGGTCTAGTCAA
7 F:GAGGTGCTGGCAGTGTCC
R:GCGGCCCGCCGCCCCCGCCGCTTGCCACTCTCTCCCTGAT
8/9 F:GCGGCCCGCCGCCCCCGCCGTGGGCCTTTG
R:TCTAGAAAGGGGCCCTGAAT
10 F:CTACCCGGAGAGCTTGACAG
R:TTCCCACTCCCTTCCTTACC
11 F:GCCCCCGCCGCCTGAGCCTTGTCTCCCTTC
R:GCGGCCCGCCGCCCCCGCCGTGCAGGATTTGGAAGACAAA
12 F:CCCCTGTTGTTCACACCTCT
R:GGGTTATTTTTCTTTGGCTTCABMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/4
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Results
Phenotype Analysis
A 45 year-old Caucasian woman with a history of parox-
ysmal atrial fibrillation, sick sinus syndrome, dilated car-
diomyopathy, and fatigue was seen in the University of
Chicago's Cardiovascular Genetics Clinic for evaluation
and treatment. The patient is a member of a large kindred
previously described [1,9,10]. The patient was evaluated
by EKG (Figure 1) that demonstrated marked sinus brady-
cardia and first degree atrioventricular block. An echocar-
diogram showed moderate dilation of the left ventricle
(5.3 cm end diastolic internal diameter) and mild dilation
of the right ventricle. The left ventricular performance was
estimated as the lower end of normal with a normal frac-
tional shortening (42%) (Figure 2). The patient reported
no neuromuscular complaints, and on physical exam
showed no overt muscle weakness.
The pedigree for this proband is shown in Figure 3. All
affected individuals had undergone pacemaker implanta-
tion for symptomatic bradycardia. Her mother reported
fatigue and was also noted to have an abnormal skeletal
muscle biopsy. Because of her marked fatigue and family
history of sudden death, a dual chamber pacemaker and
automatic defibrillator were implanted. Of note, the
proband reported an improvement in her fatigue symp-
toms after pacer implantation. With pacemaker implanta-
tion, her baseline heart rate improved from 40 bpm to 80
bpm.
Genotype Analysis
All twelve exons of LMNA were screened by denaturing
high performance liquid chromatography (DHPLC) and
single strand conformation polymorphism (SSCP) (Fig-
ure 4). In exon 5, a two bp (CT) deletion was detected in
the LMNA gene (Figure 5). The two bp deletion falls into
positions 908 and 909 of the NCBI Accession #
NM_170708 where 1 is the first coding nucleotide. This
frameshift mutation is expected to disrupt the lamin A
and C sequences after the first 302 amino acids. In addi-
tion, 26 novel amino acids (CPAQPAPEAAGSQGGEASR-
PGGLTGP) are added after the truncation. The relatively
high proline content of this additional sequence and the
positioning of this truncation would be expected to
EKG Figure 1
EKG Shown is the 12 lead electrocardiogram performed prior to pacemaker-defibrillator implantation. Each box represents 
200 msec. Sinus bradycardia is present; the proband's baseline heart rate was 45 beats per minute (normal is 80 beats per 
minute). First degree atrioventricular heart block is present (circled) as the conduction time between the atrial deflection and 
the ventricular deflection is 240 msec (normal is up to 200 msec).BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/4
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disrupt the second half of the coiled-coil region of the pro-
tein. An additional 98 unrelated subjects with dilated car-
diomyopathy were screened by SSCP and DHPLC and
found not to carry the 908_909delCT mutation. Finally,
100 chromosomes from control DNA samples were
checked and found not to carry the 908_909delCT
mutation.
Discussion
Our findings demonstrate a novel mutation in lamin A/C
in a proband whose family was previously linked to DCM
with conduction disease and chromosome 1q21.2 locus
[9]. Mutations in the LMNA gene associated with DCM
have a more severe prognosis and higher-event rates com-
pared to individuals with DCM that do not have LMNA
mutations [20]. A recent report describing another family
with a LMNA mutation causing DCM and conduction sys-
tem disease documents the need for permanent pace-
maker implantation [21]. Previous reports on the
proband's kindred support a high-event rate in family
members often resulting in sudden cardiac death even in
family members with permanent pacemakers [10]. For
example, ten out of 38 family members with pacemakers
for high-grade atrioventricular block died suddenly. Sub-
jects with LMNA mutations should be carefully evaluated
for both pacemakers and defibrillators.
It is presently unknown whether autosomal dominant
lamin A/C mutations impart their phenotype through
dominant negative or haploinsufficient mechanisms. The
Echo Figure 2
Echo Shown is an M-mode echocardiogram through the diameter of the left ventricle revealing mild dilation. The left vertical 
line marks the dimension of the ventricle in diastole at its greatest, and this dimension is 5.3 cm (above the 95th percentile for 
body mass index). The fractional shortening was normal and the ejection fraction was read as low normal consistent with the 
mildly dilated left ventricle.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/4
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majority of reported LMNA mutations are missense. In
this case, the mutant protein is thought to be expressed
and to act through a dominant interfering mechanism. A
smaller number of LMNA  mutations are frameshifting
and are expected to create truncated lamin A and C. In at
least one case, a nonsense mutation at amino acid posi-
tion 6 was described [11]. This mutation is effectively a
null allele and therefore, dominant mutations, at least in
this case, would be expected to arise from haploinsuffi-
ciency of lamin A/C. Of note, mice with a null allele in
lmna display a phenotype only in the homozygous state
[22]. The mutation we now describe is predicted to gener-
ate a substantial protein fragment consisting of the first 37
KDa of lamin A/C. The novel, proline-rich sequence that
is predicted at the carboxyl terminus of the truncated
lamin A/C may further interfere with lamin function.
Lamins assemble into a higher order structure and trunca-
tions may interfere with this assembly. The presence of
aberrantly assembled lamin filaments may also interfere
with other lamin-interacting proteins such as emerin or
nesprin-1α [23].
The exact mechanism by which LMNA mutations cause
disease is not clearly elucidated at this time. However, it is
clear that mutations in LMNA cause tissue-specific disease
affecting various differentiated cells including cardiac and
skeletal muscle, adipocytes and neurons. This suggests
that lamin's role at the nuclear membrane affects both
cell-type and tissue-specific processes. Currently, there are
at least two theories regarding the effects of LMNA [24].
The first postulates that disruptions of the inner nuclear
membrane affect heterochromatin scaffolding and
thereby gene expression. In this model, lamin A/C is nec-
essary for the appropriate expression of tissue-specific
genes. The second theory, the mechanical stress hypothe-
sis, suggests weakness in the nuclear lamina leaves certain
tissues more prone to damage by force. This model was
first raised when LMNA mutations were primarily associ-
ated with disorders affecting striated muscle [24]. Interest-
ingly, the preferential involvement of the specialized cells
of the cardiac conduction system may support less the
stress hypothesis as the cells of the atrioventricular node
are less expected to undergo considerable deformation.
The additional phenotypes now associated with LMNA
mutations also favor alternative mechanisms of
pathogenicity.
Conduction disease preceded the development of dilated
cardiomyopathy in the proband's family [1,10]. This indi-
cates the necessity for careful documentation of a three-
generation pedigree in the evaluation of patients with
conduction system disease paying particular attention to
Pedigree Figure 3
Pedigree Shown is the pedigree ascertained from the proband (indicated with an asterisk). Affected individuals are shown in 
black. Each affected individual had undergone pacemaker implantation for bradycardia. Shown in gray are individuals with a his-
tory of heart disease or sudden death.BMC Medical Genetics 2003, 4 http://www.biomedcentral.com/1471-2350/4/4
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sudden death, arrhythmia and bradycardia. Genotyping
of patients with conduction disease and DCM may pro-
vide important information regarding device implanta-
tion. Genetic counseling for patients and family members
should always accompany genetic testing as variable
expressivity and age dependent penetrance may influence
clinical decision making [25].
Conclusions
Individuals with DCM and conduction system disease
should be screened by family history and genetic testing.
Those found to have mutations in lamin A/C should be
evaluated for placement of pacemakers and automatic
defibrillators in order to prevent the sudden cardiac death
associated with this disease.
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DHPLC Figure 4
DHPLC A. DHPLC was used to detect an aberrant migra-
tion pattern (green) in the proband's DNA. The arrow indi-
cates the polymorphism that correlates with the 2 bp 
deletion. B. Sequence analysis of LMNA exon 5 amplified 
directly from the proband's DNA revealed double-banding 
indicative of a frameshift mutation. To isolate the mutant 
allele, SSCP was used. Sequence of the mutant allele revealed 
a two bp deletion (top sequence). This deletion is predicted 
to truncate lamin A/C at amino acid 302 and add a novel 26 
amino acids. The predicted protein product, if made, would 
be approximately 37 KDa and would disrupt the helical 
nature of lamin A/C and lack the carboxy-terminal globular 
region.
Digest with AlwN I to confirm the 908_909delCT mutation Figure 5
Digest with AlwN I to confirm the 908_909delCT 
mutation. The 908_909delCT mutation creates a novel 
AlwN I restriction site. Exon 5 was amplified from the 
proband and control genomic DNA and subsequently 
digested with AlwN I. Where control DNA lacks an AlwN I 
site (294 bp), the proband's exon 5 was digested with AlwN I 
generating fragments of 194 bp and 119 bp. DNA from 100 
ethnically-matched control chromosomes was similarly 
checked for this mutation and did not have the 
908_909delCT mutation. Lane 1, control; Lane 2, proband; 
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